(AOF) – Eli Lilly today announced the completion of its acquisition of Point Biopharma Global Inc., a biotech company with a pipeline of clinical and preclinical radioligand therapies in development for the treatment of cancer. Lilly’s tender offer to acquire all of Point’s issued and outstanding common stock at a purchase price of $12.50 per share in cash, expired as scheduled on December 22, 2023, and was not extended further.
The group announced at the beginning of October the acquisition of this company specializing in the development of anti-cancer therapies for $1.4 billion. Point’s common stock will be delisted from Nasdaq.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
